Scpharmaceuticals Inc Overview
Industry: Biotechnology
Sector: Healthcare
scPharmaceuticals Inc., a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. The company's lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion in patients with heart failure. Its product pipeline also includes scCeftriaxone, an antibiotic to treat infections caused by gram-positive and gram-negative organisms; and scCarbapenem program, an antibiotic for treating infections caused by gram-negative organisms. The company has a development agreement with West Pharmaceutical Services, Inc. for development of single use SmartDose device. The company was incorporated in 2013 and is headquartered in Burlington, Massachusetts.
Scpharmaceuticals Inc is evaluated using Mavefund's quality framework: growing earnings, durable profit margins, conservative leverage, strong return on equity, and disciplined share repurchases.
Score
Price History & Performance
Review Scpharmaceuticals Inc in context before unlocking the interactive price chart, financial overlays, and downloadable ratio tables.
Recent News
Scpharmaceuticals Inc Competitors
Scpharmaceuticals Inc operates in the Biotechnology industry within the Healthcare sector. Unlock the full page to compare peer rankings, valuation quality, profitability, leverage, and growth trends.
Earnings Per Share
EPS quality is one of the core Mavefund signals. Sign up to continue into the detailed EPS, ROE, margin, share buyback, leverage, and financial ratio analysis.
Continue the analysis
Sign up to unlock ROE, net margin, share buyback, leverage, financial ratios, peer charts, and downloads.
View plans